


Curriculum Vitae

	Name in Full	Jun-Hyung Cho
	Country	Korea
	Affiliation	Digestive Disease Center, Soonchunhyang University Hospital, Seoul, Korea
	Email	chojhmd@naver.com

Educational Background
<p>1996 – 2002: M.D., College of Medicine, Kyung Hee University, Seoul, Korea</p> <p>2002 – 2003: Internship, Kyung Hee University Hospital, Seoul, Korea</p> <p>2006 – 2010: Residentsip, Internal Medicine, Bundang Jesaeng General Hospital, Seongnam, Korea</p> <p>2010 – 2012: Fellowship, Department of Gastroenterology, Kyung Hee University Hospital, Seoul, Korea</p> <p>2012 – 2013: Fellowship, Digestive Disease Center, Soonchunhyang University Hospital, Seoul, Korea</p>

Professional Carrer
<p>2013 – 2017: Assistant Professor, Digestive Disease Center, Soonchunhyang University Hospital, Seoul, Korea</p> <p>2018 – 2022: Associate Professor, Digestive Disease Center, Soonchunhyang University Hospital, Seoul, Korea</p> <p>2023 – present: Professor, Digestive Disease Center, Soonchunhyang University Hospital, Seoul, Korea</p> <p>2014 – 2015: Member, ESD Study Group of Korean Society of Gastrointestinal Endoscopy</p> <p>2016 – 2019: Member, Research Group for Endoscopic Instruments and Stents of Korean Society of Gastrointestinal Endoscopy</p> <p>2018 – 2019: Member, Quality Management Committee of Korean Society of Gastrointestinal Endoscopy</p> <p>2024 – present: 'Microorganisms' Editorial board member</p>

Research Field

Main Research Interests

Management for Helicobacter pylori-related gastritis
Individualized surveillance strategy for high risk group of gastric cancer
Endoscopic diagnosis and treatment for upper gastrointestinal lesions

Publications

Cho JH, Jin SY. Efficacy and Safety of Modified Bismuth Quadruple Therapy for First-Line Helicobacter pylori Eradication: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *Microorganisms*. 2025 Feb 26;13(3):519.

Cho JH, Jin SY, Park S. Comparison of tegoprazan and proton pump inhibitors for first-line Helicobacter pylori eradication: a systematic review with meta-analysis. *Expert Rev Anti Infect Ther*. 2025 Feb-Apr;23(2-4):227-233.

Cho JH, Jin SY. Comparison of Amoxicillin Administered Twice versus Four Times a Day in First-Line Helicobacter pylori Eradication Using Tegoprazan, Clarithromycin, and Bismuth: A Propensity Score Matching Analysis. *Microorganisms*. 2024 Sep 27;12(10):1952.

Cho JH. Bismuth add-on improves the efficacy of 2-week tegoprazan-based triple therapy for first-line Helicobacter pylori eradication: a real-world evidence study. *Expert Rev Anti Infect Ther*. 2024 Sep;22(9):793-799.

Cho JH, Jin SY. Current guidelines for Helicobacter pylori treatment in East Asia 2022: Differences among China, Japan, and South Korea. *World J Clin Cases*. 2022 Jul 6;10(19):6349-6359.

Cho JH, Jin SY, Park S. Comparison of tailored Helicobacter pylori eradication versus modified bismuth quadruple therapy in Korea: a randomized controlled trial. *Expert Rev Anti Infect Ther*. 2022 Jun;20(6):923-929.

Cho JH, Jin SY. Optimized diagnosis of Helicobacter pylori and tailored eradication therapy for preventing gastric cancer: a proposal for SHAKE strategy. *Expert Rev Gastroenterol Hepatol*. 2020 Jul;14(7):553-564.

Cho JH, Jeon SR, Kim HG, Jin SY, Park S. Cost-effectiveness of a tailored Helicobacter pylori eradication strategy based on the presence of a 23S ribosomal RNA point mutation that causes clarithromycin resistance in Korean patients. *J Gastroenterol Hepatol*. 2019 Apr;34(4):700-706.